The use of stem cells and other nontraditional cells for human therapy is becoming an area of increasing importance for media formulation. Nutrient and other requirements for expanding populations of therapeutic cells to commercial scale vary widely from those for production cells.
Many therapeutic cells are anchorage-dependent and have been generated in serum-supplemented or serum-free culture containing components of animal origin. Eventually, since these cells and tissues are introduced into human patients, the cells must be brought into compliance with standards for production cells.
“In many cases, this means redeveloping culture media to replace nonhuman animal origin components with human-derived or animal-origin-free components,” notes Stephen F. Gorfien, Ph.D., director, bioproduction products and PD-Direct® Media Services at Life Technologies. “These modifications are difficult owing to the dependence of the cells on various growth factors, cytokines, and attachment factors, recombinant or synthetic forms of which may not be commercially available at reasonable cost.”
Invitrogen offers a service, PD-Direct® Bioprocess, which among other things helps companies used to working with suspension cultures of production cells migrate therapeutic cell lines from anchorage-dependent to suspension-dependent status.